Emtricitabine News and Research

RSS

Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Vaginal ring and oral PrEP found to be safe for HIV prevention among pregnant cisgender women

The monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were each found to be safe for HIV prevention among cisgender women who started using one of them in their second trimester of pregnancy, according to findings presented today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

5 Mar 2024

New early phase study evaluates “on-demand” HIV prevention method for women

A fast-dissolving vaginal insert that women would use at or around the time of sex as an "on-demand" HIV prevention method is being evaluated in a new early phase study being conducted by MATRIX, a United States Agency for International Development (USAID)-funded project focused on the early research and development of innovative HIV prevention products for women.

7 Dec 2023

Major UK study finds high demand and efficacy for HIV PrEP among sexual health service attendees

HIV PrEP requirement, duration, uptake, and usage among sexual health services (SHS) attendees in England.

4 Dec 2023

Comparing HIV PrEP medications: Study explores hypertension risk in adults on TAF vs. TDF

The risk of hypertension and statin initiation in adults starting Human Immunodeficiency Virus Pre-exposure prophylaxis.

13 Sep 2023

Study reveals substantial gap in PrEP access in more than one-third of New England colleges and universities

Young gay, bisexual, and other men who have sex with men (MSM), accounted for 80% of new HIV infections among youth ages 13–24 in 2018 and represents a priority population for HIV prevention.

24 Jul 2023

The decision-making process for the launch of trials for COVID-19 repurposed antivirals

Researchers reviewed the decision-making process for performing randomized clinical trials for three drugs under consideration for repurposing for COVID-19 treatment: remdesivir, molnupiravir, and tenofovir disoproxil fumarate.

30 Mar 2023

Two newer simplified HIV treatment options found to be at least as effective as the standard of care

Two newer simplified treatment options are at least as effective as current approaches, according to the results of a world-first international clinical trial into second-line HIV therapy led by the Kirby Institute at UNSW Sydney and presented today at the Conference on Retroviruses and Opportunistic Infections in Seattle.

23 Feb 2023

Use of dapivirine vaginal ring during third trimester of pregnancy poses no safety concerns

A vaginal ring containing the antiretroviral drug dapivirine posed no safety concerns when used in the third trimester of pregnancy, according to results to date from the first study of the dapivirine ring during pregnancy and one of only a few studies of an HIV prevention product in pregnant cisgender women.

20 Feb 2023

Study reports two cases of ocular MPox in HIV-infected patients

Researchers review the symptoms, diagnosis, and treatment of ocular Mpox syndrome in men living with HIV infection.

7 Feb 2023

Monkeypox infection in a smallpox-vaccinated patient

In a recent study published in the Emerging Infectious Diseases journal, researchers at Madigan Army Medical Center assessed the characteristics of monkeypox infection in a patient vaccinated against smallpox.

20 Sep 2022

Monkeypox virus infection in an immunocompromised patient

Researchers assessed the manifestations of the monkeypox infection in an immunocompromised patient.

19 Sep 2022

FDA approval of long-acting injectable drug marks a vital expansion of HIV prevention options

Yesterday the U.S. Food and Drug Administration announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months.

21 Dec 2021

Study: Adolescent girls and young women can and will use HIV prevention products with consistency

Adolescent girls and young women can and will use HIV prevention products with consistency, according to interim results of a study of two different methods: daily use of the antiretroviral (ARV) tablet Truvada as oral pre-exposure prophylaxis (PrEP) and the monthly dapivirine vaginal ring, a new HIV prevention product currently under regulatory review in several countries.

15 Jul 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

PrEP prescription can make a positive difference in women who inject drugs

When taken daily, pre-exposure prophylaxis, or PrEP, is a highly effective way to prevent HIV transmission, according to the Centers for Disease Control and Prevention.

16 Dec 2020

New insight into role of autophagy in controlling SARS-CoV-2 infection

A team of researchers at the University of Manitoba in Canada said that nanoparticle targeting of autophagy at the sites could be a potent tool to effectively overcome COVID-19 while preventing the common adverse effects of the drug.

2 Dec 2020

Cabotegravir highly effective in preventing HIV among women

UNAIDS has been strongly encouraged by groundbreaking new study results showing that the antiretroviral medicine cabotegravir administered by an injection every two months – prevents HIV among women.

10 Nov 2020

HIV drugs cause immune-system changes that can improve resistance to viral infections

Drugs currently used to keep the HIV virus in check also cause immune-system changes that might make humans better able to resist viral infections – but might also cause harmful inflammation, according to a study published today in Cell Reports Medicine.

23 Sep 2020

Researchers launch study to evaluate safety of HIV prevention methods in breastfeeding women

The development of safe and effective HIV prevention methods for cisgender women has long been a global health priority, yet research in women during pregnancy and breastfeeding, when they are most vulnerable to infection, has lagged years behind.

31 Aug 2020

NIH study: Long-acting form of HIV prevention drug more effective than daily oral pill

A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by the National Institutes of Health.

7 Jul 2020